SCHEMBL4165153

SCHEMBL4165153

Cc1ccncc1NC(=O)c1ccnc2[nH]c(-c3ccc(N4CCN(C)CC4)cc3)nc12

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 8/20 0.52
GSK3A P49840 3/20 0.52
TNKS O95271 2/20 0.44
PARP1 P09874 2/20 0.44
TNKS2 Q9H2K2 2/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C18 P33260 1/20 0.43
CYP2C19 P33261 1/20 0.43
KCNH2 Q12809 1/20 0.43
AURKA O14965 1/20 0.42
TTK P33981 1/20 0.42
AURKB Q96GD4 1/20 0.42
INCENP Q9NQS7 1/20 0.42
JAK2 O60674 1/20 0.41
LCK P06239 2/20 0.41
MAPK14 Q16539 2/20 0.41
PIM2 Q9P1W9 1/20 0.40
KDR P35968 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4153410 0.93 GSK3B (0.59) GSK3BGSK3AAURKAJAK2PIM2
SCHEMBL4149980 0.92 GSK3B (0.58) GSK3BGSK3AAURKATTKAURKB
SCHEMBL4148276 0.91 GSK3B (0.52) GSK3BGSK3APARP1JAK2MAPK14
SCHEMBL4165085 0.90 GSK3B (0.45) GSK3BGSK3ATNKSPARP1TNKS2
SCHEMBL4161485 0.87 GSK3B (0.57) GSK3BGSK3ACYP1A2CYP2C18CYP2C19
SCHEMBL4145011 0.87 GSK3B (0.70) GSK3BGSK3ATNKSPARP1TNKS2
SCHEMBL4152659 0.87 GSK3B (0.44) GSK3BGSK3ATNKSPARP1TNKS2
SCHEMBL4160814 0.85 LRRK2 (0.53) GSK3BGSK3AAURKAJAK2KDR
SCHEMBL4152895 0.85 GSK3B (0.60) GSK3BGSK3A
SCHEMBL4145735 0.84 GSK3B (0.53) GSK3BCYP2C19JAK2LCKMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885GSK3A 2/4885TNKS 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.